| Original language | English (US) |
|---|---|
| Pages (from-to) | 136-139 |
| Number of pages | 4 |
| Journal | Journal of Cardiac Failure |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2025 |
Funding
Disclosures: Dr. Khouri reports institutional research support from Pfizer, BridgeBio Pharma, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals; consulting/advisory board support from BridgeBio Pharma and Alnylam Pharmaceuticals, and is a member of Alnylam Pharmaceuticals Speaker's Bureau. Dr. Olabisi receives research support from National Institute on Minority Health and Health Disparities (5R01-MD016401) Dr. Alexander has received an investigator-initiated research grant from Alnylam and consulting fees with Arbor Biotechnologies, Attralus, Intellia, and Prothena. Dr. Shah reports research funding through sponsored research agreements to Duke University from Astra Zeneca, Lilly Inc., Verily Inc. and nference; co-inventor on unlicensed patents held by Duke University. Dr. Selvaraj receives research support from the National Heart, Lung, and Blood Institute (K23HL161348), Doris Duke Charitable Foundation (#2020061), American Heart Association (#935275), the Mandel Foundation, Duke Heart Center Leadership Council, the Institute for Translational Medicine and Therapeutics, and Foundation for Sarcoidosis Research. He has participated in advisory boards for AstraZeneca . The other authors report no relevant disclosures.
Keywords
- Amyloidosis
- V142I
- transthyretin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine